<DOC>
	<DOCNO>NCT00170833</DOCNO>
	<brief_summary>This study ass safety efficacy everolimus basiliximab , corticosteroid low level versus high level tacrolimus de novo renal transplant recipient .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Everolimus With Lower Versus Higher Levels Tacrolimus de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male female patient 18 65 year age Male female patient primary cadaveric , live unrelated nonHLA identical living relate donor renal transplant recipients The renal cold ischemic time ( CIT ) must &lt; 30 hour The age donor must 10 59 year meet UNOS expand donor criterion Exclusion criterion Patients meet follow criterion baseline exclude study participation . Patients previously receive organ transplant Patients recipient multiple organ transplant Recipients non heartbeating donor organ Other protocol define inclusion/exclusion criterion may apply . Patients recipient ABO incompatible transplant Tcell crossmatch positive transplant Patients current panel reactive Tcell antibody ( PRA ) titers 50 % ( test perform dithiothreitol treated patient 's serum ) Patients known positive hepatitis C serology , human immunodeficiency virus ( HIV ) Hepatitis B surface antigen positive . Laboratory result obtain within 6 month prior first dose everolimus acceptable . Recipients organs donor test positive Hepatitis B surface antigen Hepatitis C exclude Presence cardiac disease ( Old New York Heart Association Classification Grade 3 , elevate creatine phosphokinase myocardial binding isoenzyme ( CPKMB ) cardiac disease consider unsafe study investigator ) 10.Presence severe hypercholesterolemia ( 350 mg/dL , 9.1 mmoL/dL ) hypertriglyceridemia ( 500mg/dL , 5.6 mmoL/L ) . Patients control hyperlipidemia acceptable 11.White blood cell ( WBC ) count 4500/mm3 , platelet count 100,000/mm3 12.Evidence liver injury indicate abnormal liver profile ( AST , ALT , alkaline phosphatase total bilirubin 3 time ULN ) transplantation 13.Presence severe allergy require acute ( within 4 week baseline ) chronic treatment , hypersensitivity drug similar everolimus ( e.g. , macrolides ) 14.The use investigational drug within 4 week baseline period 15.Patients treat nonprotocol immunosuppressive drug treatment within 1 month prior first dose everolimus 16.Patients severe systemic infection 17.Existence surgical medical condition , current transplant , opinion investigator , preclude enrollment trial 18.Malignancy ( current history within last 5 year ) except successfully treat localize basal squamous cell carcinoma skin 19.Patients medical condition require longterm anticoagulation , heparin , low molecular weight heparin , warfarin , transplantation ( Low dose aspirin , clopidogrel , cilostazol treatment allow ) 20.Abnormal physical laboratory finding clinical significance within 2 week prior first dose everolimus investigator discretion would interfere objective study 21.Breast feed woman 22.Patients symptom significant somatic mental illness . Unresolved history drug alcohol abuse 23.Inability cooperate communicate investigator 24.Donors meet UNOS expand donor criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Renal/Kidney , transplantation , everolimus , calcineurin sparing</keyword>
</DOC>